QA: NEKTAR THERAPEUTICS in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0000906709_2023_NEKTAR_THERAPEUTICS.pdf

Logs

info Added remainder_ComprehensiveNetIncome directly from 10K industry.us_generic {}

Graph

Absolute values for 0000906709, NEKTAR THERAPEUTICS

  xvar xval
0 AssetsCurrent 545,968,000
1 IntangibleAssetsNetIncludingGoodwill 76,501,000
2 PropertyPlantAndEquipmentNet 32,451,000
3 remainder_Assets 55,680,000
4 LiabilitiesCurrent 68,204,000
5 LiabilitiesNoncurrent 120,380,000
6 remainder_Liabilities 155,378,000
7 CostOfGoodsAndServicesSold 21,635,000
8 SellingGeneralAndAdministrativeExpense 92,333,000
9 ResearchAndDevelopmentExpense 218,323,000
10 remainder_Expenses 139,145,000
11 remainder_Revenues 92,055,000
12 remainder_NetIncome 11,183,000
13 remainder_ComprehensiveNetIncome -2,750,000
  yvar yval
0 Assets 710,600,000
1 Liabilities 343,962,000
2 Expenses 471,436,000
3 Revenues 92,055,000
4 StockholdersEquity 366,638,000
5 NetIncome -368,198,000
6 ComprehensiveNetIncome -369,573,000
7 BaseVar 815,993,000
8 EconomicCapitalRatio 0.495

Edgar->Model Mapping

Feature Distribution

Change over Time